Clinical Trials Logo
  1. Home
  2. Schizophrenic Disorders
  3. NCT00660595

Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Schizophrenic Disorders Clinical Trial

Official title:
A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Clinical Trial Summary

This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00660595
Study type Interventional
Source AstraZeneca
Contact
Status Terminated
Phase Phase 3
Start date September 2008
Completion date December 2008
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04608032 - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia N/A
Completed NCT02655172 - Have a Good Grasp of the Worldthe World N/A
Completed NCT01606436 - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Phase 1
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Completed NCT02525315 - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations Phase 2
Completed NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Phase 3
Completed NCT00088491 - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Phase 3
Completed NCT01279213 - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia Phase 4
Completed NCT00600756 - Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Phase 3
Completed NCT00572247 - The Psychiatric Rehabilitation Approach to Weight Loss N/A
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Completed NCT00485823 - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Phase 4
Active, not recruiting NCT00161408 - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia N/A
Terminated NCT05164289 - Interest of EMDR Schizophrenic Disorders
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Completed NCT00088465 - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder Phase 3
Withdrawn NCT02654405 - Sodium Butyrate For Improving Cognitive Function In Schizophrenia Phase 2/Phase 3
Completed NCT02544516 - Upside Down, Give me the Handle N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2